Few categories in aesthetic medicine have moved from unknown to ubiquitous as quickly as exosomes. Five years ago the word appeared mainly in cell biology journals. It now appears on clinic price lists across London, most often attached to scalp treatments for hair thinning. The gap between the underlying science and the marketing around it is wide enough that patients deserve a careful account of what is actually known.
What an exosome actually is
Exosomes are small extracellular vesicles released by cells. They carry proteins, lipids and various forms of RNA, and they act as a mechanism by which one cell influences the behaviour of another. This is a real and well-characterised part of cell biology, and it is studied seriously across regenerative medicine, oncology and immunology.
The interest for hair loss follows from a specific observation. Research into hair follicle biology has repeatedly pointed to signalling between the dermal papilla, the cells that regulate the hair growth cycle, and the surrounding follicular structures. If the signalling environment influences whether a follicle stays in its growth phase, then a treatment that alters that environment is at least a plausible intervention. That plausibility is what has driven the interest, and it is genuine rather than invented.
Plausible is not the same as proven. Between a mechanism that makes sense in a laboratory and a treatment that reliably regrows hair in patients sits a great deal of clinical work, and that work is at an early stage.
How London clinics actually use them
The typical protocol is consistent across the city. The scalp is treated with microneedling to create controlled microchannels, and a preparation described as exosome-containing is applied topically to the treated area so that it can penetrate the disrupted barrier. Sessions are usually delivered as a course of three or four, spaced two to four weeks apart, with maintenance afterwards.
Note what this is not. It is not usually an injection of a licensed medicine, and it is not a stem cell treatment, despite the loose way both terms are sometimes used in marketing. The distinction matters, because the regulatory framework and the evidence base differ enormously between those categories.
Preparations vary substantially between suppliers. Source, purification, characterisation and concentration all differ, and none of it is visible to the patient. Two clinics offering an exosome scalp treatment at similar prices may be applying materially different products. Ask what the product is called, who supplies it and what its regulatory status is, and expect a specific answer.
Where the evidence actually sits
An accurate summary has four parts.
- Preclinical work is genuinely interesting. Laboratory and animal research on extracellular vesicles and follicular signalling is an active field with real findings behind it.
- Clinical evidence in aesthetic use is early. Published clinical work in humans for hair loss is limited in volume, often small in scale, and frequently lacks the controls and follow-up needed to draw firm conclusions.
- Microneedling is a confounder. Microneedling of the scalp on its own has a plausible effect on hair growth. Where a protocol combines microneedling with a topical preparation, disentangling the contribution of each requires study designs that mostly have not been done at scale.
- Established therapy has a much stronger base. Conventional medical treatment for pattern hair loss rests on considerably more evidence than any regenerative addition currently does.
The reasonable conclusion is not that the category is worthless. It is that a patient paying several thousand pounds for a course deserves to be told plainly which of these four statements applies to their treatment.
A practitioner who tells you the evidence is early is not undermining the treatment. They are giving you the information you are paying them for.
The regulatory position
This is the part patients most often misunderstand. A product being available for a clinic to buy is not the same as a product being licensed for a therapeutic claim in the United Kingdom. Biological preparations of this kind sit in a complex and evolving regulatory space, and the framework differs between countries, which is one reason protocols common in some markets are approached differently here.
The practical questions for a patient are specific. What is the product called and who makes it? What is its regulatory status in the United Kingdom? Is it being applied topically or injected, and does that change its status? Where is it stored and how? Who is performing the microneedling, what is their training, and is the clinic registered with the Care Quality Commission where the activity is regulated? A practitioner who answers all of those without hesitating has thought about the framework. One who deflects has not.
Where it belongs in a hair loss pathway
The most useful thing to say about exosome scalp treatment is where it sits in the order of operations, and the answer is not first.
- Diagnosis first. Pattern hair loss, telogen effluvium, scarring alopecia and nutritional, thyroid or autoimmune causes look alike and are managed completely differently. Any clinic offering treatment before establishing the cause is selling rather than treating.
- Established medical therapy next. For pattern loss, conventional topical and, where appropriate, oral treatment has by far the strongest evidence base and by far the lowest cost.
- Regenerative additions after that, for patients with miniaturising follicles still present, as an adjunct rather than a replacement.
- Surgery where appropriate, once loss has stabilised and with ongoing medical management, since transplantation relocates hair rather than stopping the process.
Used in that order, a regenerative scalp protocol is a reasonable addition for the right patient. Used as a first move, in place of a diagnosis and in place of medical therapy, it is an expensive way to postpone the treatment most likely to work.
What it costs in London
| Item | Indicative range | Note |
|---|---|---|
| Assessment with scalp examination | £100 to £300 | The step that should come first |
| Exosome-based scalp session | £400 to £900 | Course of three or four |
| Course of three, typical | £1,200 to £2,700 | Before maintenance |
| Polynucleotide scalp session | £280 to £550 | Alternative regenerative option |
| Platelet-rich plasma session | £350 to £700 | Longer track record |
Availability follows adoption. Shoreditch clinics took the category up earliest and price most competitively. Central London practices working specifically on regenerative approaches, including Mesglo London, sit at the more clinical end of the market, where treatment tends to follow assessment rather than replace it. Whichever district you choose, the sequence matters more than the postcode: find out what is happening to your hair, treat the cause, and add the extras afterwards.